Immunoadsorption, current status and future developments

Expert Opin Investig Drugs. 2000 Sep;9(9):2017-38. doi: 10.1517/13543784.9.9.2017.


The association of abnormalities in the cellular and humoral immune system with various autoimmune diseases provides the rationale for apheresis technologies. While plasmapheresis or plasma exchange is limited by its non-selective removal of all plasma components, modern apheresis techniques aim to provide more specific elimination according to clinical needs and avoid plasma product replacement. However, the commercialisation has not met the expectations in the early 80's and the number of patients treated by extracorporeal immunoadsorption remains small due to a lack of well-defined controlled trials and limited reimbursement. This review highlights the immunological and technical basis for extracorporeal immunoadsorption, as well as its current status in the treatment of immunologically-mediated diseases.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigen-Antibody Complex / drug effects
  • Antigen-Antibody Complex / immunology*
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / immunology
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology
  • Complement Activation / immunology*
  • Hemophilia A / drug therapy
  • Hemophilia A / immunology
  • Humans
  • Immune System / drug effects
  • Immune System / immunology
  • Immunoglobulins / immunology
  • Immunosorbents / immunology
  • Immunosorbents / pharmacology
  • Immunosorbents / therapeutic use*
  • Kidney Diseases / drug therapy
  • Kidney Diseases / immunology
  • Ligands
  • Nervous System Diseases / drug therapy
  • Nervous System Diseases / immunology
  • Plasmapheresis / methods


  • Antigen-Antibody Complex
  • Immunoglobulins
  • Immunosorbents
  • Ligands